Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director | September 14, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date September 14, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,560 |
Reported balance
After 2026-09-14 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-09-14 · Exercise / conversion · Acquired 130 · Balance 6,560 |
| Common StockSEC Table I · non-derivative | Direct | 6,430 |
Reported balance
After 2026-09-14 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-09-14 · Sale · Disposed 130 · Balance 6,430 F1: This transaction was executed in multiple trades at prices ranging from $505.76 to $505.985. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 5,580 |
Reported balance
After 2026-09-14 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-09-14 · Sale · Disposed 98 · Balance 5,580 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $110.86 · Expires 2028-10-31 | Direct | 6,430 |
Reported balance
After 2026-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-14 · Exercise / conversion · Disposed 130 · Balance 6,430 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $505.76 to $505.985. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2019 Filed Jan 16, 2020 21:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 2,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-001787 · form4.xml · nonDerivative · entry 1 Mesa Nilda · CIK 0001756697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares received upon vesting of restricted stock units on October 31, 2019. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 20:22 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 6,310 | $0.00 Strike: $76.36 | $0.00 |
DisclosureSEC source: 0001127602-19-023023 · form4.xml · derivative · entry 2 Mesa Nilda · CIK 0001756697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,310 Underlying: Common Stock · 6,310 shares Expires 2029-06-26 F4 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F5 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 20:22 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 2,300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-023023 · form4.xml · derivative · entry 1 Mesa Nilda · CIK 0001756697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires 2029-06-26 F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F3 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:08 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 2,660 | $110.86 Strike: $0.00 | $294,887.60 |
DisclosureSEC source: 0001127602-18-031597 · form4.xml · derivative · entry 2 Mesa Nilda · CIK 0001756697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,660 Underlying: Common Stock · 2,660 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F3 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:08 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 6,560 | $110.86 Strike: $110.86 | $727,241.60 |
DisclosureSEC source: 0001127602-18-031597 · form4.xml · derivative · entry 1 Mesa Nilda · CIK 0001756697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,560 Underlying: Common Stock · 6,560 shares Expires 2028-10-31 F1 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F1 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.